JP2010535801A - 依存症治療方法 - Google Patents
依存症治療方法 Download PDFInfo
- Publication number
- JP2010535801A JP2010535801A JP2010520285A JP2010520285A JP2010535801A JP 2010535801 A JP2010535801 A JP 2010535801A JP 2010520285 A JP2010520285 A JP 2010520285A JP 2010520285 A JP2010520285 A JP 2010520285A JP 2010535801 A JP2010535801 A JP 2010535801A
- Authority
- JP
- Japan
- Prior art keywords
- nepicastat
- cocaine
- dopamine
- compound
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010012335 Dependence Diseases 0.000 title description 7
- 239000000126 substance Substances 0.000 claims abstract description 125
- 238000000034 method Methods 0.000 claims abstract description 123
- 229940126062 Compound A Drugs 0.000 claims abstract description 119
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims abstract description 119
- 208000024891 symptom Diseases 0.000 claims abstract description 86
- 201000009032 substance abuse Diseases 0.000 claims abstract description 78
- 208000022497 Cocaine-Related disease Diseases 0.000 claims abstract description 41
- 206010013663 drug dependence Diseases 0.000 claims abstract description 25
- 201000006145 cocaine dependence Diseases 0.000 claims abstract description 23
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims description 322
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims description 304
- 229960003638 dopamine Drugs 0.000 claims description 159
- 229960003920 cocaine Drugs 0.000 claims description 151
- 238000011282 treatment Methods 0.000 claims description 115
- 230000000694 effects Effects 0.000 claims description 113
- 239000003795 chemical substances by application Substances 0.000 claims description 93
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 81
- 102100033156 Dopamine beta-hydroxylase Human genes 0.000 claims description 68
- 239000003814 drug Substances 0.000 claims description 67
- 238000011084 recovery Methods 0.000 claims description 67
- 230000001965 increasing effect Effects 0.000 claims description 66
- 229940079593 drug Drugs 0.000 claims description 56
- 230000001419 dependent effect Effects 0.000 claims description 39
- 239000004031 partial agonist Substances 0.000 claims description 33
- 239000003112 inhibitor Substances 0.000 claims description 32
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims description 31
- 235000019788 craving Nutrition 0.000 claims description 29
- 238000012360 testing method Methods 0.000 claims description 29
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 27
- 230000003247 decreasing effect Effects 0.000 claims description 27
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims description 26
- 229960002715 nicotine Drugs 0.000 claims description 26
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims description 26
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims description 25
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims description 25
- 230000002093 peripheral effect Effects 0.000 claims description 24
- 206010013654 Drug abuse Diseases 0.000 claims description 23
- 230000036961 partial effect Effects 0.000 claims description 21
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims description 20
- 230000002459 sustained effect Effects 0.000 claims description 20
- 108010015720 Dopamine beta-Hydroxylase Proteins 0.000 claims description 19
- 239000000556 agonist Substances 0.000 claims description 19
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical group C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 claims description 17
- 208000019901 Anxiety disease Diseases 0.000 claims description 17
- 241000208125 Nicotiana Species 0.000 claims description 17
- 235000002637 Nicotiana tabacum Nutrition 0.000 claims description 17
- 239000000674 adrenergic antagonist Substances 0.000 claims description 17
- 201000001272 cocaine abuse Diseases 0.000 claims description 17
- -1 inhalants Substances 0.000 claims description 17
- YNQLUTRBYVCPMQ-UHFFFAOYSA-N Ethylbenzene Chemical compound CCC1=CC=CC=C1 YNQLUTRBYVCPMQ-UHFFFAOYSA-N 0.000 claims description 16
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical group CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 claims description 16
- URLKBWYHVLBVBO-UHFFFAOYSA-N Para-Xylene Chemical group CC1=CC=C(C)C=C1 URLKBWYHVLBVBO-UHFFFAOYSA-N 0.000 claims description 16
- 230000008033 biological extinction Effects 0.000 claims description 16
- 239000002532 enzyme inhibitor Substances 0.000 claims description 16
- ZQBFAOFFOQMSGJ-UHFFFAOYSA-N hexafluorobenzene Chemical compound FC1=C(F)C(F)=C(F)C(F)=C1F ZQBFAOFFOQMSGJ-UHFFFAOYSA-N 0.000 claims description 16
- IVSZLXZYQVIEFR-UHFFFAOYSA-N m-xylene Chemical group CC1=CC=CC(C)=C1 IVSZLXZYQVIEFR-UHFFFAOYSA-N 0.000 claims description 16
- UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 16
- 229940121991 Serotonin and norepinephrine reuptake inhibitor Drugs 0.000 claims description 15
- 239000000935 antidepressant agent Substances 0.000 claims description 15
- 229940005513 antidepressants Drugs 0.000 claims description 15
- 229940125532 enzyme inhibitor Drugs 0.000 claims description 15
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 claims description 15
- 229940127221 norepinephrine reuptake inhibitor Drugs 0.000 claims description 15
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 claims description 15
- 239000003775 serotonin noradrenalin reuptake inhibitor Substances 0.000 claims description 15
- 230000015572 biosynthetic process Effects 0.000 claims description 14
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 claims description 14
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 claims description 14
- 241001539473 Euphoria Species 0.000 claims description 13
- 206010015535 Euphoric mood Diseases 0.000 claims description 13
- 230000003400 hallucinatory effect Effects 0.000 claims description 13
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 claims description 12
- 102000012289 Corticotropin-Releasing Hormone Human genes 0.000 claims description 12
- 108010022152 Corticotropin-Releasing Hormone Proteins 0.000 claims description 12
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 claims description 12
- 229940025084 amphetamine Drugs 0.000 claims description 12
- 238000012423 maintenance Methods 0.000 claims description 12
- 239000002899 monoamine oxidase inhibitor Substances 0.000 claims description 12
- 229940122439 Hydroxylase inhibitor Drugs 0.000 claims description 11
- 230000036506 anxiety Effects 0.000 claims description 11
- 230000003340 mental effect Effects 0.000 claims description 11
- 229940044551 receptor antagonist Drugs 0.000 claims description 11
- 239000002464 receptor antagonist Substances 0.000 claims description 11
- 102000005962 receptors Human genes 0.000 claims description 11
- 108020003175 receptors Proteins 0.000 claims description 11
- 230000009467 reduction Effects 0.000 claims description 11
- 238000003786 synthesis reaction Methods 0.000 claims description 11
- 229940124597 therapeutic agent Drugs 0.000 claims description 11
- USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 claims description 10
- VAYOSLLFUXYJDT-RDTXWAMCSA-N Lysergic acid diethylamide Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N(CC)CC)C2)=C3C2=CNC3=C1 VAYOSLLFUXYJDT-RDTXWAMCSA-N 0.000 claims description 10
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 claims description 10
- 239000000695 adrenergic alpha-agonist Substances 0.000 claims description 10
- 102000004305 alpha Adrenergic Receptors Human genes 0.000 claims description 10
- 108090000861 alpha Adrenergic Receptors Proteins 0.000 claims description 10
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims description 10
- 229950002454 lysergide Drugs 0.000 claims description 10
- 230000002503 metabolic effect Effects 0.000 claims description 10
- 229960001797 methadone Drugs 0.000 claims description 10
- 239000004050 mood stabilizer Substances 0.000 claims description 10
- 229940127237 mood stabilizer Drugs 0.000 claims description 10
- 229950010883 phencyclidine Drugs 0.000 claims description 10
- 208000019116 sleep disease Diseases 0.000 claims description 10
- 230000001225 therapeutic effect Effects 0.000 claims description 10
- KWTSXDURSIMDCE-UHFFFAOYSA-N 1-phenylpropan-2-amine Chemical group CC(N)CC1=CC=CC=C1 KWTSXDURSIMDCE-UHFFFAOYSA-N 0.000 claims description 9
- 102000035038 5-HT1 receptors Human genes 0.000 claims description 9
- 108091005478 5-HT1 receptors Proteins 0.000 claims description 9
- 229940123702 Adenosine A2a receptor antagonist Drugs 0.000 claims description 9
- 235000001674 Agaricus brunnescens Nutrition 0.000 claims description 9
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims description 9
- 229940127291 Calcium channel antagonist Drugs 0.000 claims description 9
- 241000218236 Cannabis Species 0.000 claims description 9
- 229940122459 Glutamate antagonist Drugs 0.000 claims description 9
- ZPXSCAKFGYXMGA-UHFFFAOYSA-N Mazindol Chemical compound N12CCN=C2C2=CC=CC=C2C1(O)C1=CC=C(Cl)C=C1 ZPXSCAKFGYXMGA-UHFFFAOYSA-N 0.000 claims description 9
- DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 claims description 9
- 102000003840 Opioid Receptors Human genes 0.000 claims description 9
- 108090000137 Opioid Receptors Proteins 0.000 claims description 9
- 229940123257 Opioid receptor antagonist Drugs 0.000 claims description 9
- 239000008896 Opium Substances 0.000 claims description 9
- 229940123445 Tricyclic antidepressant Drugs 0.000 claims description 9
- 239000002467 adenosine A2a receptor antagonist Substances 0.000 claims description 9
- 239000005557 antagonist Substances 0.000 claims description 9
- 239000001961 anticonvulsive agent Substances 0.000 claims description 9
- 229940049706 benzodiazepine Drugs 0.000 claims description 9
- 239000000480 calcium channel blocker Substances 0.000 claims description 9
- OFZCIYFFPZCNJE-UHFFFAOYSA-N carisoprodol Chemical compound NC(=O)OCC(C)(CCC)COC(=O)NC(C)C OFZCIYFFPZCNJE-UHFFFAOYSA-N 0.000 claims description 9
- 229960004587 carisoprodol Drugs 0.000 claims description 9
- 229960000299 mazindol Drugs 0.000 claims description 9
- 229960001344 methylphenidate Drugs 0.000 claims description 9
- 239000003401 opiate antagonist Substances 0.000 claims description 9
- 229960001027 opium Drugs 0.000 claims description 9
- 230000000306 recurrent effect Effects 0.000 claims description 9
- 239000003215 serotonin 5-HT2 receptor antagonist Substances 0.000 claims description 9
- 229940125794 sodium channel blocker Drugs 0.000 claims description 9
- 239000003195 sodium channel blocking agent Substances 0.000 claims description 9
- 239000003029 tricyclic antidepressant agent Substances 0.000 claims description 9
- WACNXHCZHTVBJM-UHFFFAOYSA-N 1,2,3,4,5-pentafluorobenzene Chemical compound FC1=CC(F)=C(F)C(F)=C1F WACNXHCZHTVBJM-UHFFFAOYSA-N 0.000 claims description 8
- GOYDNIKZWGIXJT-UHFFFAOYSA-N 1,2-difluorobenzene Chemical compound FC1=CC=CC=C1F GOYDNIKZWGIXJT-UHFFFAOYSA-N 0.000 claims description 8
- JXUKFFRPLNTYIV-UHFFFAOYSA-N 1,3,5-trifluorobenzene Chemical compound FC1=CC(F)=CC(F)=C1 JXUKFFRPLNTYIV-UHFFFAOYSA-N 0.000 claims description 8
- YEJRWHAVMIAJKC-UHFFFAOYSA-N 4-Butyrolactone Chemical compound O=C1CCCO1 YEJRWHAVMIAJKC-UHFFFAOYSA-N 0.000 claims description 8
- 238000013019 agitation Methods 0.000 claims description 8
- 230000001773 anti-convulsant effect Effects 0.000 claims description 8
- 230000001430 anti-depressive effect Effects 0.000 claims description 8
- 229960003965 antiepileptics Drugs 0.000 claims description 8
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims description 8
- 102000012740 beta Adrenergic Receptors Human genes 0.000 claims description 8
- 108010079452 beta Adrenergic Receptors Proteins 0.000 claims description 8
- 239000003825 glutamate receptor antagonist Substances 0.000 claims description 8
- PYLWMHQQBFSUBP-UHFFFAOYSA-N monofluorobenzene Chemical compound FC1=CC=CC=C1 PYLWMHQQBFSUBP-UHFFFAOYSA-N 0.000 claims description 8
- 229940078552 o-xylene Drugs 0.000 claims description 8
- 229940005483 opioid analgesics Drugs 0.000 claims description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 8
- 102000015554 Dopamine receptor Human genes 0.000 claims description 7
- 108050004812 Dopamine receptor Proteins 0.000 claims description 7
- 208000002193 Pain Diseases 0.000 claims description 7
- 230000000561 anti-psychotic effect Effects 0.000 claims description 7
- 206010003119 arrhythmia Diseases 0.000 claims description 7
- 230000006793 arrhythmia Effects 0.000 claims description 7
- 210000005036 nerve Anatomy 0.000 claims description 7
- 230000036407 pain Effects 0.000 claims description 7
- 230000007958 sleep Effects 0.000 claims description 7
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 claims description 6
- 206010001497 Agitation Diseases 0.000 claims description 6
- 229940099362 Catechol O methyltransferase inhibitor Drugs 0.000 claims description 6
- 206010008479 Chest Pain Diseases 0.000 claims description 6
- 102000004980 Dopamine D2 Receptors Human genes 0.000 claims description 6
- 108090001111 Dopamine D2 Receptors Proteins 0.000 claims description 6
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 claims description 6
- 229940086616 Monoamine oxidase B inhibitor Drugs 0.000 claims description 6
- 206010028813 Nausea Diseases 0.000 claims description 6
- 239000012190 activator Substances 0.000 claims description 6
- 229940121359 adenosine receptor antagonist Drugs 0.000 claims description 6
- 239000003543 catechol methyltransferase inhibitor Substances 0.000 claims description 6
- 230000003920 cognitive function Effects 0.000 claims description 6
- 229960002069 diamorphine Drugs 0.000 claims description 6
- 239000000221 dopamine uptake inhibitor Substances 0.000 claims description 6
- 239000000380 hallucinogen Substances 0.000 claims description 6
- 230000008693 nausea Effects 0.000 claims description 6
- 239000000296 purinergic P1 receptor antagonist Substances 0.000 claims description 6
- 229940076279 serotonin Drugs 0.000 claims description 6
- DBGIVFWFUFKIQN-UHFFFAOYSA-N (+-)-Fenfluramine Chemical compound CCNC(C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-UHFFFAOYSA-N 0.000 claims description 5
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 claims description 5
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 claims description 5
- SHXWCVYOXRDMCX-UHFFFAOYSA-N 3,4-methylenedioxymethamphetamine Chemical group CNC(C)CC1=CC=C2OCOC2=C1 SHXWCVYOXRDMCX-UHFFFAOYSA-N 0.000 claims description 5
- 208000031229 Cardiomyopathies Diseases 0.000 claims description 5
- 229940094659 Dopamine reuptake inhibitor Drugs 0.000 claims description 5
- 208000000059 Dyspnea Diseases 0.000 claims description 5
- 206010013975 Dyspnoeas Diseases 0.000 claims description 5
- 206010016059 Facial pain Diseases 0.000 claims description 5
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims description 5
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 claims description 5
- 206010028735 Nasal congestion Diseases 0.000 claims description 5
- 206010033557 Palpitations Diseases 0.000 claims description 5
- 206010039509 Scab Diseases 0.000 claims description 5
- 206010047700 Vomiting Diseases 0.000 claims description 5
- 229940035676 analgesics Drugs 0.000 claims description 5
- 229940035674 anesthetics Drugs 0.000 claims description 5
- 239000000730 antalgic agent Substances 0.000 claims description 5
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 claims description 5
- 229940125715 antihistaminic agent Drugs 0.000 claims description 5
- 239000000739 antihistaminic agent Substances 0.000 claims description 5
- 239000002249 anxiolytic agent Substances 0.000 claims description 5
- 230000000949 anxiolytic effect Effects 0.000 claims description 5
- 229940005530 anxiolytics Drugs 0.000 claims description 5
- 206010006451 bronchitis Diseases 0.000 claims description 5
- 229960001948 caffeine Drugs 0.000 claims description 5
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims description 5
- 229930003827 cannabinoid Natural products 0.000 claims description 5
- 239000003557 cannabinoid Substances 0.000 claims description 5
- PUAQLLVFLMYYJJ-ZETCQYMHSA-N cathinone Chemical compound C[C@H](N)C(=O)C1=CC=CC=C1 PUAQLLVFLMYYJJ-ZETCQYMHSA-N 0.000 claims description 5
- 239000000812 cholinergic antagonist Substances 0.000 claims description 5
- 238000009225 cognitive behavioral therapy Methods 0.000 claims description 5
- 229960000632 dexamfetamine Drugs 0.000 claims description 5
- XXEPPPIWZFICOJ-UHFFFAOYSA-N diethylpropion Chemical compound CCN(CC)C(C)C(=O)C1=CC=CC=C1 XXEPPPIWZFICOJ-UHFFFAOYSA-N 0.000 claims description 5
- 229960004890 diethylpropion Drugs 0.000 claims description 5
- XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 claims description 5
- 208000002173 dizziness Diseases 0.000 claims description 5
- 239000003136 dopamine receptor stimulating agent Substances 0.000 claims description 5
- 208000001780 epistaxis Diseases 0.000 claims description 5
- 229960001582 fenfluramine Drugs 0.000 claims description 5
- 239000003193 general anesthetic agent Substances 0.000 claims description 5
- 235000003642 hunger Nutrition 0.000 claims description 5
- LLPOLZWFYMWNKH-CMKMFDCUSA-N hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 claims description 5
- 229960000240 hydrocodone Drugs 0.000 claims description 5
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 claims description 5
- 206010021654 increased appetite Diseases 0.000 claims description 5
- 229960003299 ketamine Drugs 0.000 claims description 5
- 229960001252 methamphetamine Drugs 0.000 claims description 5
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 claims description 5
- 229940035363 muscle relaxants Drugs 0.000 claims description 5
- 239000003158 myorelaxant agent Substances 0.000 claims description 5
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 5
- 239000000820 nonprescription drug Substances 0.000 claims description 5
- 229960002085 oxycodone Drugs 0.000 claims description 5
- 229960000761 pemoline Drugs 0.000 claims description 5
- NRNCYVBFPDDJNE-UHFFFAOYSA-N pemoline Chemical compound O1C(N)=NC(=O)C1C1=CC=CC=C1 NRNCYVBFPDDJNE-UHFFFAOYSA-N 0.000 claims description 5
- 229960003209 phenmetrazine Drugs 0.000 claims description 5
- 239000000932 sedative agent Substances 0.000 claims description 5
- 229940125723 sedative agent Drugs 0.000 claims description 5
- 208000013220 shortness of breath Diseases 0.000 claims description 5
- 229960004380 tramadol Drugs 0.000 claims description 5
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 claims description 5
- 239000003204 tranquilizing agent Substances 0.000 claims description 5
- 230000002936 tranquilizing effect Effects 0.000 claims description 5
- LLPOLZWFYMWNKH-UHFFFAOYSA-N trans-dihydrocodeinone Natural products C1C(N(CCC234)C)C2CCC(=O)C3OC2=C4C1=CC=C2OC LLPOLZWFYMWNKH-UHFFFAOYSA-N 0.000 claims description 5
- 230000008673 vomiting Effects 0.000 claims description 5
- YFGHCGITMMYXAQ-UHFFFAOYSA-N 2-[(diphenylmethyl)sulfinyl]acetamide Chemical compound C=1C=CC=CC=1C(S(=O)CC(=O)N)C1=CC=CC=C1 YFGHCGITMMYXAQ-UHFFFAOYSA-N 0.000 claims description 4
- SJZRECIVHVDYJC-UHFFFAOYSA-N 4-hydroxybutyric acid Chemical compound OCCCC(O)=O SJZRECIVHVDYJC-UHFFFAOYSA-N 0.000 claims description 4
- 229940098778 Dopamine receptor agonist Drugs 0.000 claims description 4
- 206010013754 Drug withdrawal syndrome Diseases 0.000 claims description 4
- 206010019233 Headaches Diseases 0.000 claims description 4
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims description 4
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims description 4
- 206010028741 Nasal inflammation Diseases 0.000 claims description 4
- 108010040718 Neurokinin-1 Receptors Proteins 0.000 claims description 4
- 102100037346 Substance-P receptor Human genes 0.000 claims description 4
- AFCGFAGUEYAMAO-UHFFFAOYSA-N acamprosate Chemical compound CC(=O)NCCCS(O)(=O)=O AFCGFAGUEYAMAO-UHFFFAOYSA-N 0.000 claims description 4
- 229960004047 acamprosate Drugs 0.000 claims description 4
- 150000001557 benzodiazepines Chemical class 0.000 claims description 4
- 229940065144 cannabinoids Drugs 0.000 claims description 4
- 230000002996 emotional effect Effects 0.000 claims description 4
- 231100000869 headache Toxicity 0.000 claims description 4
- 229960004502 levodopa Drugs 0.000 claims description 4
- 230000033001 locomotion Effects 0.000 claims description 4
- 230000004060 metabolic process Effects 0.000 claims description 4
- 229960001165 modafinil Drugs 0.000 claims description 4
- 208000010125 myocardial infarction Diseases 0.000 claims description 4
- OOBHFESNSZDWIU-UHFFFAOYSA-N phenmetrazine Chemical compound CC1NCCOC1C1=CC=CC=C1 OOBHFESNSZDWIU-UHFFFAOYSA-N 0.000 claims description 4
- 230000035945 sensitivity Effects 0.000 claims description 4
- 208000022925 sleep disturbance Diseases 0.000 claims description 4
- 230000001149 cognitive effect Effects 0.000 claims description 3
- 230000003111 delayed effect Effects 0.000 claims description 3
- 208000029436 dilated pupil Diseases 0.000 claims description 3
- 230000002085 persistent effect Effects 0.000 claims description 3
- 239000000164 antipsychotic agent Substances 0.000 claims description 2
- APJYDQYYACXCRM-UHFFFAOYSA-N tryptamine Chemical compound C1=CC=C2C(CCN)=CNC2=C1 APJYDQYYACXCRM-UHFFFAOYSA-N 0.000 claims 4
- PEBWOGPSYUIOBP-UHFFFAOYSA-N 1,2,4-trifluorobenzene Chemical compound FC1=CC=C(F)C(F)=C1 PEBWOGPSYUIOBP-UHFFFAOYSA-N 0.000 claims 2
- MMZYCBHLNZVROM-UHFFFAOYSA-N 1-fluoro-2-methylbenzene Chemical compound CC1=CC=CC=C1F MMZYCBHLNZVROM-UHFFFAOYSA-N 0.000 claims 2
- 239000002269 analeptic agent Substances 0.000 claims 2
- 230000001095 motoneuron effect Effects 0.000 claims 2
- OOBHFESNSZDWIU-GXSJLCMTSA-N (2s,3s)-3-methyl-2-phenylmorpholine Chemical compound C[C@@H]1NCCO[C@H]1C1=CC=CC=C1 OOBHFESNSZDWIU-GXSJLCMTSA-N 0.000 claims 1
- HXTGXYRHXAGCFP-OAQYLSRUSA-N (r)-(2,3-dimethoxyphenyl)-[1-[2-(4-fluorophenyl)ethyl]piperidin-4-yl]methanol Chemical compound COC1=CC=CC([C@H](O)C2CCN(CCC=3C=CC(F)=CC=3)CC2)=C1OC HXTGXYRHXAGCFP-OAQYLSRUSA-N 0.000 claims 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 1
- 208000012886 Vertigo Diseases 0.000 claims 1
- 239000003194 amino acid receptor blocking agent Substances 0.000 claims 1
- 229940125681 anticonvulsant agent Drugs 0.000 claims 1
- 229940005529 antipsychotics Drugs 0.000 claims 1
- 239000003772 serotonin uptake inhibitor Substances 0.000 claims 1
- 231100000889 vertigo Toxicity 0.000 claims 1
- 229950005868 nepicastat Drugs 0.000 description 264
- YZZVIKDAOTXDEB-JTQLQIEISA-N nepicastat Chemical compound NCC1=CNC(=S)N1[C@@H]1CC2=CC(F)=CC(F)=C2CC1 YZZVIKDAOTXDEB-JTQLQIEISA-N 0.000 description 263
- 229960002748 norepinephrine Drugs 0.000 description 164
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 164
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 163
- 238000011699 spontaneously hypertensive rat Methods 0.000 description 63
- AUZONCFQVSMFAP-UHFFFAOYSA-N disulfiram Chemical compound CCN(CC)C(=S)SSC(=S)N(CC)CC AUZONCFQVSMFAP-UHFFFAOYSA-N 0.000 description 60
- 208000011117 substance-related disease Diseases 0.000 description 60
- 101000927562 Homo sapiens Dopamine beta-hydroxylase Proteins 0.000 description 54
- 241000700159 Rattus Species 0.000 description 53
- 210000001519 tissue Anatomy 0.000 description 49
- 150000001875 compounds Chemical class 0.000 description 45
- 210000003975 mesenteric artery Anatomy 0.000 description 45
- 241000282472 Canis lupus familiaris Species 0.000 description 44
- 210000005240 left ventricle Anatomy 0.000 description 43
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 40
- 230000002829 reductive effect Effects 0.000 description 40
- 230000007423 decrease Effects 0.000 description 37
- WPMVQUHUCQAOBU-UHFFFAOYSA-N 3-[(3,5-difluorophenyl)methyl]-1h-imidazole-2-thione Chemical compound FC1=CC(F)=CC(CN2C(=NC=C2)S)=C1 WPMVQUHUCQAOBU-UHFFFAOYSA-N 0.000 description 35
- 241001465754 Metazoa Species 0.000 description 34
- 210000003710 cerebral cortex Anatomy 0.000 description 34
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 30
- 230000036772 blood pressure Effects 0.000 description 30
- 229960002563 disulfiram Drugs 0.000 description 30
- 239000000902 placebo Substances 0.000 description 30
- 229940068196 placebo Drugs 0.000 description 30
- 231100000736 substance abuse Toxicity 0.000 description 29
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 27
- 239000000243 solution Substances 0.000 description 27
- 238000004458 analytical method Methods 0.000 description 26
- 201000006152 substance dependence Diseases 0.000 description 26
- 210000004369 blood Anatomy 0.000 description 21
- 239000008280 blood Substances 0.000 description 21
- 210000002216 heart Anatomy 0.000 description 21
- 208000020016 psychiatric disease Diseases 0.000 description 20
- 150000003943 catecholamines Chemical class 0.000 description 19
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 18
- 102000004190 Enzymes Human genes 0.000 description 18
- 108090000790 Enzymes Proteins 0.000 description 18
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 18
- 238000006243 chemical reaction Methods 0.000 description 18
- 229940088598 enzyme Drugs 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
- 230000008859 change Effects 0.000 description 17
- 239000000203 mixture Substances 0.000 description 17
- 230000003389 potentiating effect Effects 0.000 description 17
- 206010007559 Cardiac failure congestive Diseases 0.000 description 16
- 206010019280 Heart failures Diseases 0.000 description 16
- 230000002354 daily effect Effects 0.000 description 16
- 230000005764 inhibitory process Effects 0.000 description 16
- 230000036470 plasma concentration Effects 0.000 description 16
- 239000003981 vehicle Substances 0.000 description 16
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 15
- 230000002401 inhibitory effect Effects 0.000 description 15
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 14
- 208000019022 Mood disease Diseases 0.000 description 14
- 208000026251 Opioid-Related disease Diseases 0.000 description 14
- 239000007788 liquid Substances 0.000 description 14
- DZGWFCGJZKJUFP-UHFFFAOYSA-N tyramine Chemical compound NCCC1=CC=C(O)C=C1 DZGWFCGJZKJUFP-UHFFFAOYSA-N 0.000 description 14
- 238000003556 assay Methods 0.000 description 13
- 239000002775 capsule Substances 0.000 description 13
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 13
- 229960000623 carbamazepine Drugs 0.000 description 13
- 231100000673 dose–response relationship Toxicity 0.000 description 13
- 238000001727 in vivo Methods 0.000 description 13
- 230000004044 response Effects 0.000 description 13
- 230000002889 sympathetic effect Effects 0.000 description 13
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 12
- 150000003839 salts Chemical class 0.000 description 12
- 239000000523 sample Substances 0.000 description 12
- 230000002526 effect on cardiovascular system Effects 0.000 description 11
- 239000012458 free base Substances 0.000 description 11
- PMRYVIKBURPHAH-UHFFFAOYSA-N methimazole Chemical compound CN1C=CNC1=S PMRYVIKBURPHAH-UHFFFAOYSA-N 0.000 description 11
- 201000005040 opiate dependence Diseases 0.000 description 11
- 239000011541 reaction mixture Substances 0.000 description 11
- 239000007787 solid Substances 0.000 description 11
- 238000012453 sprague-dawley rat model Methods 0.000 description 11
- 210000002700 urine Anatomy 0.000 description 11
- 229960001058 bupropion Drugs 0.000 description 10
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 description 10
- 238000004128 high performance liquid chromatography Methods 0.000 description 10
- 238000010253 intravenous injection Methods 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- 229960002178 thiamazole Drugs 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 description 9
- 230000003276 anti-hypertensive effect Effects 0.000 description 9
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 9
- PYZRQGJRPPTADH-UHFFFAOYSA-N lamotrigine Chemical compound NC1=NC(N)=NN=C1C1=CC=CC(Cl)=C1Cl PYZRQGJRPPTADH-UHFFFAOYSA-N 0.000 description 9
- 229960001848 lamotrigine Drugs 0.000 description 9
- 238000005259 measurement Methods 0.000 description 9
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 9
- 229910052757 nitrogen Inorganic materials 0.000 description 9
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 9
- 210000002254 renal artery Anatomy 0.000 description 9
- 229960004394 topiramate Drugs 0.000 description 9
- MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 description 9
- 229960000604 valproic acid Drugs 0.000 description 9
- 241000283690 Bos taurus Species 0.000 description 8
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 8
- 238000000540 analysis of variance Methods 0.000 description 8
- 210000004556 brain Anatomy 0.000 description 8
- 208000035475 disorder Diseases 0.000 description 8
- 238000000835 electrochemical detection Methods 0.000 description 8
- 238000004811 liquid chromatography Methods 0.000 description 8
- 238000002844 melting Methods 0.000 description 8
- 230000008018 melting Effects 0.000 description 8
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 7
- 229930182837 (R)-adrenaline Natural products 0.000 description 7
- 206010024264 Lethargy Diseases 0.000 description 7
- 206010057852 Nicotine dependence Diseases 0.000 description 7
- 208000025569 Tobacco Use disease Diseases 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 229960005139 epinephrine Drugs 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 238000001990 intravenous administration Methods 0.000 description 7
- 239000012044 organic layer Substances 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- 210000002820 sympathetic nervous system Anatomy 0.000 description 7
- 229960003732 tyramine Drugs 0.000 description 7
- SXPRVMIZFRCAGC-UHFFFAOYSA-N 1,2,3,4,5-pentafluoro-6-methylbenzene Chemical compound CC1=C(F)C(F)=C(F)C(F)=C1F SXPRVMIZFRCAGC-UHFFFAOYSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- 206010012239 Delusion Diseases 0.000 description 6
- 108090000371 Esterases Proteins 0.000 description 6
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 6
- 241000282412 Homo Species 0.000 description 6
- 206010020772 Hypertension Diseases 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 230000002411 adverse Effects 0.000 description 6
- 150000001412 amines Chemical class 0.000 description 6
- 230000004872 arterial blood pressure Effects 0.000 description 6
- 230000003542 behavioural effect Effects 0.000 description 6
- 230000001684 chronic effect Effects 0.000 description 6
- 231100000868 delusion Toxicity 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 6
- BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 6
- 229960003132 halothane Drugs 0.000 description 6
- 230000000004 hemodynamic effect Effects 0.000 description 6
- 229920000669 heparin Polymers 0.000 description 6
- 229960002897 heparin Drugs 0.000 description 6
- 239000010410 layer Substances 0.000 description 6
- 210000001577 neostriatum Anatomy 0.000 description 6
- 229960001816 oxcarbazepine Drugs 0.000 description 6
- CTRLABGOLIVAIY-UHFFFAOYSA-N oxcarbazepine Chemical compound C1C(=O)C2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 CTRLABGOLIVAIY-UHFFFAOYSA-N 0.000 description 6
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical group C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 6
- 238000001228 spectrum Methods 0.000 description 6
- 210000001685 thyroid gland Anatomy 0.000 description 6
- 230000002861 ventricular Effects 0.000 description 6
- 208000007848 Alcoholism Diseases 0.000 description 5
- KPYSYYIEGFHWSV-UHFFFAOYSA-N Baclofen Chemical compound OC(=O)CC(CN)C1=CC=C(Cl)C=C1 KPYSYYIEGFHWSV-UHFFFAOYSA-N 0.000 description 5
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 5
- 208000004547 Hallucinations Diseases 0.000 description 5
- 108090000783 Renin Proteins 0.000 description 5
- 102100028255 Renin Human genes 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 210000001367 artery Anatomy 0.000 description 5
- 229960000794 baclofen Drugs 0.000 description 5
- 239000000969 carrier Substances 0.000 description 5
- 238000004296 chiral HPLC Methods 0.000 description 5
- 230000008034 disappearance Effects 0.000 description 5
- 230000009429 distress Effects 0.000 description 5
- 238000010828 elution Methods 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 206010016256 fatigue Diseases 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 description 5
- 229960003086 naltrexone Drugs 0.000 description 5
- 229960001576 octopamine Drugs 0.000 description 5
- 238000001543 one-way ANOVA Methods 0.000 description 5
- 229960001412 pentobarbital Drugs 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000011002 quantification Methods 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 230000000638 stimulation Effects 0.000 description 5
- 230000035882 stress Effects 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 229960002431 trimipramine Drugs 0.000 description 5
- ZSCDBOWYZJWBIY-UHFFFAOYSA-N trimipramine Chemical compound C1CC2=CC=CC=C2N(CC(CN(C)C)C)C2=CC=CC=C21 ZSCDBOWYZJWBIY-UHFFFAOYSA-N 0.000 description 5
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 4
- QHGUCRYDKWKLMG-QMMMGPOBSA-N (R)-octopamine Chemical compound NC[C@H](O)C1=CC=C(O)C=C1 QHGUCRYDKWKLMG-QMMMGPOBSA-N 0.000 description 4
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 4
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 4
- 206010010904 Convulsion Diseases 0.000 description 4
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 4
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 4
- QHGUCRYDKWKLMG-MRVPVSSYSA-N Octopamine Natural products NC[C@@H](O)C1=CC=C(O)C=C1 QHGUCRYDKWKLMG-MRVPVSSYSA-N 0.000 description 4
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 4
- 229960003805 amantadine Drugs 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 235000010323 ascorbic acid Nutrition 0.000 description 4
- 229960005070 ascorbic acid Drugs 0.000 description 4
- 239000011668 ascorbic acid Substances 0.000 description 4
- 150000001540 azides Chemical class 0.000 description 4
- 230000006399 behavior Effects 0.000 description 4
- 230000027455 binding Effects 0.000 description 4
- 239000012267 brine Substances 0.000 description 4
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 4
- 229960002802 bromocriptine Drugs 0.000 description 4
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 4
- 229960001736 buprenorphine Drugs 0.000 description 4
- 229960002896 clonidine Drugs 0.000 description 4
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
- 229960003914 desipramine Drugs 0.000 description 4
- 230000029142 excretion Effects 0.000 description 4
- 229960002464 fluoxetine Drugs 0.000 description 4
- 229960000647 gepirone Drugs 0.000 description 4
- QOIGKGMMAGJZNZ-UHFFFAOYSA-N gepirone Chemical compound O=C1CC(C)(C)CC(=O)N1CCCCN1CCN(C=2N=CC=CN=2)CC1 QOIGKGMMAGJZNZ-UHFFFAOYSA-N 0.000 description 4
- 230000001631 hypertensive effect Effects 0.000 description 4
- 229960004801 imipramine Drugs 0.000 description 4
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 239000011630 iodine Substances 0.000 description 4
- 229910052740 iodine Inorganic materials 0.000 description 4
- TYQCGQRIZGCHNB-JLAZNSOCSA-N l-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 4
- 229910052744 lithium Inorganic materials 0.000 description 4
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 4
- 229960004127 naloxone Drugs 0.000 description 4
- 230000007383 nerve stimulation Effects 0.000 description 4
- 229960000715 nimodipine Drugs 0.000 description 4
- 150000002825 nitriles Chemical class 0.000 description 4
- YEHCICAEULNIGD-MZMPZRCHSA-N pergolide Chemical compound C1=CC([C@H]2C[C@@H](CSC)CN([C@@H]2C2)CCC)=C3C2=CNC3=C1 YEHCICAEULNIGD-MZMPZRCHSA-N 0.000 description 4
- 229960004851 pergolide Drugs 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 229960002036 phenytoin Drugs 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 229950009626 ritanserin Drugs 0.000 description 4
- JUQLTPCYUFPYKE-UHFFFAOYSA-N ritanserin Chemical compound CC=1N=C2SC=CN2C(=O)C=1CCN(CC1)CCC1=C(C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 JUQLTPCYUFPYKE-UHFFFAOYSA-N 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 3
- WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 description 3
- ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 description 3
- AJKNNUJQFALRIK-UHFFFAOYSA-N 1,2,3-trifluorobenzene Chemical compound FC1=CC=CC(F)=C1F AJKNNUJQFALRIK-UHFFFAOYSA-N 0.000 description 3
- DETXZQGDWUJKMO-UHFFFAOYSA-N 2-hydroxymethanesulfonic acid Chemical compound OCS(O)(=O)=O DETXZQGDWUJKMO-UHFFFAOYSA-N 0.000 description 3
- 239000003477 4 aminobutyric acid receptor stimulating agent Substances 0.000 description 3
- DIPDUAJWNBEVOY-PPHPATTJSA-N 4-(aminomethyl)-3-[(2s)-5,7-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl]-1h-imidazole-2-thione;hydrochloride Chemical compound Cl.NCC1=CNC(=S)N1[C@@H]1CC2=CC(F)=CC(F)=C2CC1 DIPDUAJWNBEVOY-PPHPATTJSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 102000005369 Aldehyde Dehydrogenase Human genes 0.000 description 3
- 108020002663 Aldehyde Dehydrogenase Proteins 0.000 description 3
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- 102000016938 Catalase Human genes 0.000 description 3
- 108010053835 Catalase Proteins 0.000 description 3
- 206010010219 Compulsions Diseases 0.000 description 3
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 3
- 206010012289 Dementia Diseases 0.000 description 3
- 108010061435 Enalapril Proteins 0.000 description 3
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 3
- 239000005977 Ethylene Substances 0.000 description 3
- 208000010201 Exanthema Diseases 0.000 description 3
- 108010024636 Glutathione Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 208000003863 Marijuana Abuse Diseases 0.000 description 3
- 102000004108 Neurotransmitter Receptors Human genes 0.000 description 3
- 108090000590 Neurotransmitter Receptors Proteins 0.000 description 3
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 description 3
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 description 3
- PHVGLTMQBUFIQQ-UHFFFAOYSA-N Nortryptiline Chemical compound C1CC2=CC=CC=C2C(=CCCNC)C2=CC=CC=C21 PHVGLTMQBUFIQQ-UHFFFAOYSA-N 0.000 description 3
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 3
- 208000001431 Psychomotor Agitation Diseases 0.000 description 3
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 239000000808 adrenergic beta-agonist Substances 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 229960000836 amitriptyline Drugs 0.000 description 3
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 3
- 229960002519 amoxapine Drugs 0.000 description 3
- QWGDMFLQWFTERH-UHFFFAOYSA-N amoxapine Chemical compound C12=CC(Cl)=CC=C2OC2=CC=CC=C2N=C1N1CCNCC1 QWGDMFLQWFTERH-UHFFFAOYSA-N 0.000 description 3
- 239000012491 analyte Substances 0.000 description 3
- 229960004372 aripiprazole Drugs 0.000 description 3
- 229960002430 atomoxetine Drugs 0.000 description 3
- VHGCDTVCOLNTBX-QGZVFWFLSA-N atomoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=CC=C1C VHGCDTVCOLNTBX-QGZVFWFLSA-N 0.000 description 3
- QTAOMKOIBXZKND-PPHPATTJSA-N carbidopa Chemical group O.NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 QTAOMKOIBXZKND-PPHPATTJSA-N 0.000 description 3
- 229960004205 carbidopa Drugs 0.000 description 3
- 229940105657 catalase Drugs 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 229960001653 citalopram Drugs 0.000 description 3
- 210000003748 coronary sinus Anatomy 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 239000002288 dopamine 2 receptor stimulating agent Substances 0.000 description 3
- 229960005426 doxepin Drugs 0.000 description 3
- ODQWQRRAPPTVAG-GZTJUZNOSA-N doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 description 3
- 238000001647 drug administration Methods 0.000 description 3
- 229960002866 duloxetine Drugs 0.000 description 3
- 230000004064 dysfunction Effects 0.000 description 3
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 3
- 229960000873 enalapril Drugs 0.000 description 3
- 229960004341 escitalopram Drugs 0.000 description 3
- WSEQXVZVJXJVFP-FQEVSTJZSA-N escitalopram Chemical compound C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-FQEVSTJZSA-N 0.000 description 3
- 201000005884 exanthem Diseases 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 229960003180 glutathione Drugs 0.000 description 3
- 239000002117 illicit drug Substances 0.000 description 3
- 206010022437 insomnia Diseases 0.000 description 3
- IQVRBWUUXZMOPW-PKNBQFBNSA-N istradefylline Chemical group CN1C=2C(=O)N(CC)C(=O)N(CC)C=2N=C1\C=C\C1=CC=C(OC)C(OC)=C1 IQVRBWUUXZMOPW-PKNBQFBNSA-N 0.000 description 3
- 229950009028 istradefylline Drugs 0.000 description 3
- 230000003907 kidney function Effects 0.000 description 3
- 229960004002 levetiracetam Drugs 0.000 description 3
- HPHUVLMMVZITSG-ZCFIWIBFSA-N levetiracetam Chemical compound CC[C@H](C(N)=O)N1CCCC1=O HPHUVLMMVZITSG-ZCFIWIBFSA-N 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 210000000713 mesentery Anatomy 0.000 description 3
- 229960001785 mirtazapine Drugs 0.000 description 3
- RONZAEMNMFQXRA-UHFFFAOYSA-N mirtazapine Chemical compound C1C2=CC=CN=C2N2CCN(C)CC2C2=CC=CC=C21 RONZAEMNMFQXRA-UHFFFAOYSA-N 0.000 description 3
- 229940073569 n-methylephedrine Drugs 0.000 description 3
- 229960001158 nortriptyline Drugs 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 229960005017 olanzapine Drugs 0.000 description 3
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 description 3
- 229960002296 paroxetine Drugs 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 208000007100 phencyclidine abuse Diseases 0.000 description 3
- IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical group N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 description 3
- 229960001289 prazosin Drugs 0.000 description 3
- 229960003712 propranolol Drugs 0.000 description 3
- 229960002601 protriptyline Drugs 0.000 description 3
- BWPIARFWQZKAIA-UHFFFAOYSA-N protriptyline Chemical compound C1=CC2=CC=CC=C2C(CCCNC)C2=CC=CC=C21 BWPIARFWQZKAIA-UHFFFAOYSA-N 0.000 description 3
- 235000021251 pulses Nutrition 0.000 description 3
- 229960004431 quetiapine Drugs 0.000 description 3
- URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 description 3
- 206010037844 rash Diseases 0.000 description 3
- 230000008327 renal blood flow Effects 0.000 description 3
- 229960001534 risperidone Drugs 0.000 description 3
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 description 3
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 3
- 229960002073 sertraline Drugs 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 208000020685 sleep-wake disease Diseases 0.000 description 3
- 230000000391 smoking effect Effects 0.000 description 3
- 238000000528 statistical test Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 229940034208 thyroxine Drugs 0.000 description 3
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 3
- 238000004448 titration Methods 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 238000012034 trail making test Methods 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 238000007492 two-way ANOVA Methods 0.000 description 3
- 229960004751 varenicline Drugs 0.000 description 3
- TWYFGYXQSYOKLK-CYUSMAIQSA-N varenicline tartrate Chemical group OC(=O)[C@H](O)[C@@H](O)C(O)=O.C12=CC3=NC=CN=C3C=C2[C@H]2C[C@@H]1CNC2 TWYFGYXQSYOKLK-CYUSMAIQSA-N 0.000 description 3
- 229960004688 venlafaxine Drugs 0.000 description 3
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 description 3
- 238000011706 wistar kyoto rat Methods 0.000 description 3
- GOTMKOSCLKVOGG-OAHLLOKOSA-N (5R)-8-chloro-3-methyl-5-phenyl-1,2,4,5-tetrahydro-3-benzazepin-7-ol Chemical compound C1([C@@H]2C3=CC(O)=C(Cl)C=C3CCN(C2)C)=CC=CC=C1 GOTMKOSCLKVOGG-OAHLLOKOSA-N 0.000 description 2
- SEPPVOUBHWNCAW-FNORWQNLSA-N (E)-4-oxonon-2-enal Chemical compound CCCCCC(=O)\C=C\C=O SEPPVOUBHWNCAW-FNORWQNLSA-N 0.000 description 2
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 2
- YFMPSMITLLBENU-UHFFFAOYSA-N 3,4-dihydroxybenzylamine Chemical compound NCC1=CC=C(O)C(O)=C1 YFMPSMITLLBENU-UHFFFAOYSA-N 0.000 description 2
- YZZVIKDAOTXDEB-SNVBAGLBSA-N 4-(aminomethyl)-3-[(2r)-5,7-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl]-1h-imidazole-2-thione Chemical compound NCC1=CNC(=S)N1[C@H]1CC2=CC(F)=CC(F)=C2CC1 YZZVIKDAOTXDEB-SNVBAGLBSA-N 0.000 description 2
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 2
- LLBZPESJRQGYMB-UHFFFAOYSA-N 4-one Natural products O1C(C(=O)CC)CC(C)C11C2(C)CCC(C3(C)C(C(C)(CO)C(OC4C(C(O)C(O)C(COC5C(C(O)C(O)CO5)OC5C(C(OC6C(C(O)C(O)C(CO)O6)O)C(O)C(CO)O5)OC5C(C(O)C(O)C(C)O5)O)O4)O)CC3)CC3)=C3C2(C)CC1 LLBZPESJRQGYMB-UHFFFAOYSA-N 0.000 description 2
- HOUVATQQKYAEBB-UHFFFAOYSA-N 5,7-difluoro-3,4-dihydro-1h-naphthalen-2-one Chemical compound C1CC(=O)CC2=CC(F)=CC(F)=C21 HOUVATQQKYAEBB-UHFFFAOYSA-N 0.000 description 2
- 239000005541 ACE inhibitor Substances 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 108700028369 Alleles Proteins 0.000 description 2
- 208000029197 Amphetamine-Related disease Diseases 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 208000031104 Arterial Occlusive disease Diseases 0.000 description 2
- KZFBHCCLJSAHBQ-UHFFFAOYSA-N Benzoylecgonine Natural products CN1C2CCC1C(C(C2)OC(=C)c3ccccc3)C(=O)O KZFBHCCLJSAHBQ-UHFFFAOYSA-N 0.000 description 2
- 101000927553 Bos taurus Dopamine beta-hydroxylase Proteins 0.000 description 2
- 241000282465 Canis Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 206010010144 Completed suicide Diseases 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- DGMPVYSXXIOGJY-UHFFFAOYSA-N Fusaric acid Chemical compound CCCCC1=CC=C(C(O)=O)N=C1 DGMPVYSXXIOGJY-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 208000031886 HIV Infections Diseases 0.000 description 2
- 101100499813 Homo sapiens DBH gene Proteins 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 206010029260 Neuroblastoma Diseases 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- GQPLMRYTRLFLPF-UHFFFAOYSA-N Nitrous Oxide Chemical compound [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 2
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 2
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 2
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 2
- 206010037213 Psychomotor retardation Diseases 0.000 description 2
- 208000028017 Psychotic disease Diseases 0.000 description 2
- 206010038743 Restlessness Diseases 0.000 description 2
- 206010044565 Tremor Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000001919 adrenal effect Effects 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 230000016571 aggressive behavior Effects 0.000 description 2
- 201000007930 alcohol dependence Diseases 0.000 description 2
- 208000029650 alcohol withdrawal Diseases 0.000 description 2
- 208000022780 alcohol-induced mental disease Diseases 0.000 description 2
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 2
- 239000002220 antihypertensive agent Substances 0.000 description 2
- 229940127088 antihypertensive drug Drugs 0.000 description 2
- 208000021328 arterial occlusion Diseases 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 210000003403 autonomic nervous system Anatomy 0.000 description 2
- 239000002585 base Chemical group 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229940125388 beta agonist Drugs 0.000 description 2
- 239000002876 beta blocker Substances 0.000 description 2
- 229940097320 beta blocking agent Drugs 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000004531 blood pressure lowering effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000005013 brain tissue Anatomy 0.000 description 2
- NMJJFJNHVMGPGM-UHFFFAOYSA-N butyl formate Chemical compound CCCCOC=O NMJJFJNHVMGPGM-UHFFFAOYSA-N 0.000 description 2
- 201000001843 cannabis dependence Diseases 0.000 description 2
- 235000011089 carbon dioxide Nutrition 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 210000001715 carotid artery Anatomy 0.000 description 2
- NPAKNKYSJIDKMW-UHFFFAOYSA-N carvedilol Chemical compound COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=NC3=CC=C[CH]C3=C12 NPAKNKYSJIDKMW-UHFFFAOYSA-N 0.000 description 2
- 229960004195 carvedilol Drugs 0.000 description 2
- 230000001055 chewing effect Effects 0.000 description 2
- 238000010835 comparative analysis Methods 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 229940109239 creatinine Drugs 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 238000002224 dissection Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229940000406 drug candidate Drugs 0.000 description 2
- GVGYEFKIHJTNQZ-RFQIPJPRSA-N ecgonine benzoate Chemical compound O([C@@H]1[C@@H]([C@H]2CC[C@@H](C1)N2C)C(O)=O)C(=O)C1=CC=CC=C1 GVGYEFKIHJTNQZ-RFQIPJPRSA-N 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 238000001952 enzyme assay Methods 0.000 description 2
- 150000002148 esters Chemical group 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 239000001530 fumaric acid Substances 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 229930182480 glucuronide Natural products 0.000 description 2
- 150000008134 glucuronides Chemical class 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 208000021267 infertility disease Diseases 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000035987 intoxication Effects 0.000 description 2
- 231100000566 intoxication Toxicity 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- 210000004731 jugular vein Anatomy 0.000 description 2
- 238000007449 liver function test Methods 0.000 description 2
- 230000006742 locomotor activity Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000015654 memory Effects 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 2
- CXGFWBPQQXZELI-UHFFFAOYSA-N n-ethylpyridin-2-amine Chemical compound CCNC1=CC=CC=N1 CXGFWBPQQXZELI-UHFFFAOYSA-N 0.000 description 2
- 230000018791 negative regulation of catalytic activity Effects 0.000 description 2
- 230000002644 neurohormonal effect Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 238000009520 phase I clinical trial Methods 0.000 description 2
- 229960001802 phenylephrine Drugs 0.000 description 2
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000012495 positive regulation of renal sodium excretion Effects 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000009597 pregnancy test Methods 0.000 description 2
- 150000003140 primary amides Chemical class 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000001671 psychotherapy Methods 0.000 description 2
- 210000001147 pulmonary artery Anatomy 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 230000000284 resting effect Effects 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 238000000527 sonication Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000024188 startle response Effects 0.000 description 2
- 230000000707 stereoselective effect Effects 0.000 description 2
- 239000012089 stop solution Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000035900 sweating Effects 0.000 description 2
- 230000035488 systolic blood pressure Effects 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N thiocyanic acid Chemical compound SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 230000024883 vasodilation Effects 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- XQIONCDGNVRBQG-MRVPVSSYSA-N (2r)-5,7-difluoro-1,2,3,4-tetrahydronaphthalen-2-ol Chemical compound C1=C(F)C=C2C[C@H](O)CCC2=C1F XQIONCDGNVRBQG-MRVPVSSYSA-N 0.000 description 1
- FSXUXANZPDLESG-QRPNPIFTSA-N (2s)-5,7-difluoro-1,2,3,4-tetrahydronaphthalen-2-amine;hydrochloride Chemical compound Cl.C1=C(F)C=C2C[C@@H](N)CCC2=C1F FSXUXANZPDLESG-QRPNPIFTSA-N 0.000 description 1
- KEIFWROAQVVDBN-UHFFFAOYSA-N 1,2-dihydronaphthalene Chemical compound C1=CC=C2C=CCCC2=C1 KEIFWROAQVVDBN-UHFFFAOYSA-N 0.000 description 1
- OXFSTTJBVAAALW-UHFFFAOYSA-N 1,3-dihydroimidazole-2-thione Chemical compound SC1=NC=CN1 OXFSTTJBVAAALW-UHFFFAOYSA-N 0.000 description 1
- LDMOEFOXLIZJOW-UHFFFAOYSA-N 1-dodecanesulfonic acid Chemical compound CCCCCCCCCCCCS(O)(=O)=O LDMOEFOXLIZJOW-UHFFFAOYSA-N 0.000 description 1
- XHLHPRDBBAGVEG-UHFFFAOYSA-N 1-tetralone Chemical compound C1=CC=C2C(=O)CCCC2=C1 XHLHPRDBBAGVEG-UHFFFAOYSA-N 0.000 description 1
- GLDQAMYCGOIJDV-UHFFFAOYSA-N 2,3-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC=CC(O)=C1O GLDQAMYCGOIJDV-UHFFFAOYSA-N 0.000 description 1
- IGGNSAVLXJKCNH-UHFFFAOYSA-N 2-(3,5-difluorophenyl)acetic acid Chemical compound OC(=O)CC1=CC(F)=CC(F)=C1 IGGNSAVLXJKCNH-UHFFFAOYSA-N 0.000 description 1
- WMVPARKLYWQLNN-UHFFFAOYSA-N 2-(3,5-difluorophenyl)acetyl chloride Chemical compound FC1=CC(F)=CC(CC(Cl)=O)=C1 WMVPARKLYWQLNN-UHFFFAOYSA-N 0.000 description 1
- QDXORTKZTNOXOP-UHFFFAOYSA-N 2-amino-6-methoxyphenol Chemical compound COC1=CC=CC(N)=C1O QDXORTKZTNOXOP-UHFFFAOYSA-N 0.000 description 1
- ZKPVULIWDZEZIT-UHFFFAOYSA-N 3-(1-ethyl-3,4-dihydronaphthalen-2-yl)pyridine Chemical compound C1CC2=CC=CC=C2C(CC)=C1C1=CC=CN=C1 ZKPVULIWDZEZIT-UHFFFAOYSA-N 0.000 description 1
- IRJNJBIOUYJBHG-UHFFFAOYSA-N 3-(1-methylpyrrolidin-2-yl)pyridine Chemical compound CN1CCCC1C1=CC=CN=C1.CN1CCCC1C1=CC=CN=C1 IRJNJBIOUYJBHG-UHFFFAOYSA-N 0.000 description 1
- VYJLZWDJLXHGSW-JTQLQIEISA-N 3-[(2s)-5,7-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl]-2-sulfanylidene-1h-imidazole-4-carbonitrile Chemical compound N1([C@H]2CCC3=C(F)C=C(C=C3C2)F)C(C#N)=CNC1=S VYJLZWDJLXHGSW-JTQLQIEISA-N 0.000 description 1
- 102000049773 5-HT2A Serotonin Receptor Human genes 0.000 description 1
- 108010072564 5-HT2A Serotonin Receptor Proteins 0.000 description 1
- 102000006902 5-HT2C Serotonin Receptor Human genes 0.000 description 1
- 108010072553 5-HT2C Serotonin Receptor Proteins 0.000 description 1
- 102100022738 5-hydroxytryptamine receptor 1A Human genes 0.000 description 1
- 101710138638 5-hydroxytryptamine receptor 1A Proteins 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 108060003345 Adrenergic Receptor Proteins 0.000 description 1
- 102000017910 Adrenergic receptor Human genes 0.000 description 1
- 208000017194 Affective disease Diseases 0.000 description 1
- 206010001597 Alcohol interaction Diseases 0.000 description 1
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 1
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000031091 Amnestic disease Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 102000005862 Angiotensin II Human genes 0.000 description 1
- 101800000733 Angiotensin-2 Proteins 0.000 description 1
- 101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 description 1
- 206010003130 Arrhythmia supraventricular Diseases 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- 208000020925 Bipolar disease Diseases 0.000 description 1
- 101100499810 Bos taurus DBH gene Proteins 0.000 description 1
- 101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 206010006326 Breath odour Diseases 0.000 description 1
- 102000000584 Calmodulin Human genes 0.000 description 1
- 108010041952 Calmodulin Proteins 0.000 description 1
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 102000006378 Catechol O-methyltransferase Human genes 0.000 description 1
- 108020002739 Catechol O-methyltransferase Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010010305 Confusional state Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 102000010906 Cyclooxygenase 1 Human genes 0.000 description 1
- 108010037464 Cyclooxygenase 1 Proteins 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 101150049660 DRD2 gene Proteins 0.000 description 1
- 102100037458 Dephospho-CoA kinase Human genes 0.000 description 1
- 206010012374 Depressed mood Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010013710 Drug interaction Diseases 0.000 description 1
- 238000001061 Dunnett's test Methods 0.000 description 1
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
- 238000005727 Friedel-Crafts reaction Methods 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 description 1
- 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 1
- 102000011845 Iodide peroxidase Human genes 0.000 description 1
- 108010036012 Iodide peroxidase Proteins 0.000 description 1
- 238000012313 Kruskal-Wallis test Methods 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102100037611 Lysophospholipase Human genes 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010027940 Mood altered Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 1
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 208000006550 Mydriasis Diseases 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 108090000028 Neprilysin Proteins 0.000 description 1
- 102000003729 Neprilysin Human genes 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010033864 Paranoia Diseases 0.000 description 1
- 208000027099 Paranoid disease Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 108010010677 Phosphodiesterase I Proteins 0.000 description 1
- 108010058864 Phospholipases A2 Proteins 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 241001282135 Poromitra oscitans Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 102000003923 Protein Kinase C Human genes 0.000 description 1
- 108090000315 Protein Kinase C Proteins 0.000 description 1
- 206010037211 Psychomotor hyperactivity Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 102000001494 Sterol O-Acyltransferase Human genes 0.000 description 1
- 108010054082 Sterol O-acyltransferase Proteins 0.000 description 1
- 238000007059 Strecker synthesis reaction Methods 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 102000010861 Type 3 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 description 1
- 108010037543 Type 3 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 description 1
- 108091000117 Tyrosine 3-Monooxygenase Proteins 0.000 description 1
- 102000048218 Tyrosine 3-monooxygenases Human genes 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 206010048232 Yawning Diseases 0.000 description 1
- DBAIYVSATDTERJ-SECBINFHSA-N [(2r)-5,7-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl] methanesulfonate Chemical compound C1=C(F)C=C2C[C@H](OS(=O)(=O)C)CCC2=C1F DBAIYVSATDTERJ-SECBINFHSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 150000007513 acids Chemical group 0.000 description 1
- 229960001570 ademetionine Drugs 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 238000011292 agonist therapy Methods 0.000 description 1
- 206010001584 alcohol abuse Diseases 0.000 description 1
- 208000025746 alcohol use disease Diseases 0.000 description 1
- 208000028505 alcohol-related disease Diseases 0.000 description 1
- 229960002478 aldosterone Drugs 0.000 description 1
- 125000005219 aminonitrile group Chemical class 0.000 description 1
- 230000006986 amnesia Effects 0.000 description 1
- 201000002472 amphetamine abuse Diseases 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 229950006323 angiotensin ii Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- 229940127225 asthma medication Drugs 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- 238000013542 behavioral therapy Methods 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 238000009530 blood pressure measurement Methods 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 230000006931 brain damage Effects 0.000 description 1
- 231100000874 brain damage Toxicity 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 201000009322 cannabis abuse Diseases 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000012754 cardiac puncture Methods 0.000 description 1
- 230000007681 cardiovascular toxicity Effects 0.000 description 1
- 231100000060 cardiovascular toxicity Toxicity 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000000451 chemical ionisation Methods 0.000 description 1
- 238000007705 chemical test Methods 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 231100000762 chronic effect Toxicity 0.000 description 1
- 235000019506 cigar Nutrition 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 238000010549 co-Evaporation Methods 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 230000003930 cognitive ability Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000011340 continuous therapy Methods 0.000 description 1
- 230000009989 contractile response Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000007428 craniotomy Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 101150109673 dbh gene Proteins 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 108010049285 dephospho-CoA kinase Proteins 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- SPWVRYZQLGQKGK-UHFFFAOYSA-N dichloromethane;hexane Chemical compound ClCCl.CCCCCC SPWVRYZQLGQKGK-UHFFFAOYSA-N 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 150000002084 enol ethers Chemical group 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 230000012953 feeding on blood of other organism Effects 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 210000003191 femoral vein Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 238000012921 fluorescence analysis Methods 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- WBJINCZRORDGAQ-UHFFFAOYSA-N formic acid ethyl ester Natural products CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 210000001652 frontal lobe Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 102000054766 genetic haplotypes Human genes 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- AKRQHOWXVSDJEF-UHFFFAOYSA-N heptane-1-sulfonic acid Chemical compound CCCCCCCS(O)(=O)=O AKRQHOWXVSDJEF-UHFFFAOYSA-N 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 239000012456 homogeneous solution Substances 0.000 description 1
- 150000004677 hydrates Chemical group 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- ARRNBPCNZJXHRJ-UHFFFAOYSA-M hydron;tetrabutylazanium;phosphate Chemical compound OP(O)([O-])=O.CCCC[N+](CCCC)(CCCC)CCCC ARRNBPCNZJXHRJ-UHFFFAOYSA-M 0.000 description 1
- DOUHZFSGSXMPIE-UHFFFAOYSA-N hydroxidooxidosulfur(.) Chemical compound [O]SO DOUHZFSGSXMPIE-UHFFFAOYSA-N 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 239000000976 ink Substances 0.000 description 1
- 230000030214 innervation Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 210000000231 kidney cortex Anatomy 0.000 description 1
- 210000003246 kidney medulla Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 208000024714 major depressive disease Diseases 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-L malate(2-) Chemical compound [O-]C(=O)C(O)CC([O-])=O BJEPYKJPYRNKOW-UHFFFAOYSA-L 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 230000007510 mood change Effects 0.000 description 1
- 230000008450 motivation Effects 0.000 description 1
- 102000051367 mu Opioid Receptors Human genes 0.000 description 1
- 239000003887 narcotic antagonist Substances 0.000 description 1
- 208000011309 nasal bleeding Diseases 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000003982 neuronal uptake Effects 0.000 description 1
- 210000000607 neurosecretory system Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000002670 nicotine replacement therapy Methods 0.000 description 1
- 238000010641 nitrile hydrolysis reaction Methods 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 239000001272 nitrous oxide Substances 0.000 description 1
- 238000009828 non-uniform distribution Methods 0.000 description 1
- 230000002474 noradrenergic effect Effects 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003402 opiate agonist Substances 0.000 description 1
- 201000000988 opioid abuse Diseases 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000008533 pain sensitivity Effects 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000036581 peripheral resistance Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 231100000683 possible toxicity Toxicity 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- LJCNRYVRMXRIQR-OLXYHTOASA-L potassium sodium L-tartrate Chemical class [Na+].[K+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O LJCNRYVRMXRIQR-OLXYHTOASA-L 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- ZNNZYHKDIALBAK-UHFFFAOYSA-M potassium thiocyanate Chemical compound [K+].[S-]C#N ZNNZYHKDIALBAK-UHFFFAOYSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000955 prescription drug Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000036584 pressor response Effects 0.000 description 1
- 230000003518 presynaptic effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 229930010796 primary metabolite Natural products 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Chemical group 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 229940001470 psychoactive drug Drugs 0.000 description 1
- 230000037047 psychomotor activity Effects 0.000 description 1
- 239000004089 psychotropic agent Substances 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 238000003653 radioligand binding assay Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 229940124550 renal vasodilator Drugs 0.000 description 1
- 230000036454 renin-angiotensin system Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- QEVHRUUCFGRFIF-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C(C5=CC=C(OC)C=C5N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-MDEJGZGSSA-N 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 210000003752 saphenous vein Anatomy 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000013275 serotonin uptake Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 239000012439 solid excipient Substances 0.000 description 1
- 239000012453 solvate Chemical group 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000000934 spermatocidal agent Substances 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 229940127230 sympathomimetic drug Drugs 0.000 description 1
- 210000002504 synaptic vesicle Anatomy 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 235000019505 tobacco product Nutrition 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- JFJZZMVDLULRGK-URLMMPGGSA-O tubocurarine Chemical compound C([C@H]1[N+](C)(C)CCC=2C=C(C(=C(OC3=CC=C(C=C3)C[C@H]3C=4C=C(C(=CC=4CCN3C)OC)O3)C=21)O)OC)C1=CC=C(O)C3=C1 JFJZZMVDLULRGK-URLMMPGGSA-O 0.000 description 1
- 229960001844 tubocurarine Drugs 0.000 description 1
- 238000002211 ultraviolet spectrum Methods 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 230000036325 urinary excretion Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000003039 volatile agent Substances 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 108020001612 μ-opioid receptors Proteins 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Otolaryngology (AREA)
- Vascular Medicine (AREA)
- Anesthesiology (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US93532307P | 2007-08-06 | 2007-08-06 | |
| US95655507P | 2007-08-17 | 2007-08-17 | |
| US96059107P | 2007-10-04 | 2007-10-04 | |
| PCT/US2008/072357 WO2009021055A1 (en) | 2007-08-06 | 2008-08-06 | Methods for treating dependence |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014107381A Division JP2014148551A (ja) | 2007-08-06 | 2014-05-23 | 依存症治療方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010535801A true JP2010535801A (ja) | 2010-11-25 |
| JP2010535801A5 JP2010535801A5 (enExample) | 2011-08-04 |
Family
ID=40341713
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010520285A Pending JP2010535801A (ja) | 2007-08-06 | 2008-08-06 | 依存症治療方法 |
| JP2014107381A Pending JP2014148551A (ja) | 2007-08-06 | 2014-05-23 | 依存症治療方法 |
| JP2016162881A Pending JP2016210798A (ja) | 2007-08-06 | 2016-08-23 | 依存症治療方法 |
| JP2018108758A Pending JP2018154645A (ja) | 2007-08-06 | 2018-06-06 | 依存症治療方法 |
| JP2020081105A Pending JP2020114883A (ja) | 2007-08-06 | 2020-05-01 | 依存症治療方法 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014107381A Pending JP2014148551A (ja) | 2007-08-06 | 2014-05-23 | 依存症治療方法 |
| JP2016162881A Pending JP2016210798A (ja) | 2007-08-06 | 2016-08-23 | 依存症治療方法 |
| JP2018108758A Pending JP2018154645A (ja) | 2007-08-06 | 2018-06-06 | 依存症治療方法 |
| JP2020081105A Pending JP2020114883A (ja) | 2007-08-06 | 2020-05-01 | 依存症治療方法 |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US20090041800A1 (enExample) |
| EP (2) | EP2182804B1 (enExample) |
| JP (5) | JP2010535801A (enExample) |
| CN (2) | CN101815438A (enExample) |
| AU (1) | AU2008283903B2 (enExample) |
| BR (1) | BRPI0815089A2 (enExample) |
| CA (1) | CA2695372C (enExample) |
| CO (1) | CO6260015A2 (enExample) |
| ES (1) | ES2638190T3 (enExample) |
| IL (1) | IL257418A (enExample) |
| MX (4) | MX2010001390A (enExample) |
| NZ (1) | NZ583192A (enExample) |
| PH (1) | PH12015502210A1 (enExample) |
| RU (1) | RU2491067C2 (enExample) |
| SG (2) | SG10201705968RA (enExample) |
| WO (1) | WO2009021055A1 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2491067C2 (ru) | 2007-08-06 | 2013-08-27 | Байотай Терапис, Инк | Способы лечения зависимости |
| WO2010124089A2 (en) * | 2009-04-22 | 2010-10-28 | Synosia Therapeutics, Inc. | Methods for treating dependence |
| US9804149B2 (en) * | 2012-10-10 | 2017-10-31 | Bio-Rad Laboratories, Inc. | Patient-based results display |
| CA3042642A1 (en) | 2013-08-12 | 2015-02-19 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded immediate release abuse deterrent pill |
| WO2015095391A1 (en) | 2013-12-17 | 2015-06-25 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| US9192570B2 (en) | 2013-12-20 | 2015-11-24 | AntiOP, Inc. | Intranasal naloxone compositions and methods of making and using same |
| DK3169315T3 (da) | 2014-07-17 | 2020-08-10 | Pharmaceutical Manufacturing Res Services In | Væskefyldt doseringsform til forhindring af misbrug med øjeblikkelig frigivelse |
| AU2015336065A1 (en) | 2014-10-20 | 2017-05-04 | Pharmaceutical Manufacturing Research Services, Inc. | Extended release abuse deterrent liquid fill dosage form |
| US20170235908A1 (en) * | 2015-11-15 | 2017-08-17 | Oriah Behaviorial Health, Inc. | Systems and Methods for Managing and Treating Substance Abuse Addiction |
| CN110996912A (zh) * | 2017-08-20 | 2020-04-10 | 福摩莱克斯医药创新有限公司 | 用于鼻内递送的干粉组合物 |
| US11844859B2 (en) | 2017-08-20 | 2023-12-19 | Nasus Pharma Ltd. | Dry powder compositions for intranasal delivery |
| GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
| CN108066355A (zh) * | 2017-12-28 | 2018-05-25 | 宁夏恩多芬科技有限公司 | Nitrous Oxide作为治疗神经官能症的用途 |
| FR3093419B1 (fr) * | 2019-03-08 | 2021-06-18 | Univ Grenoble Alpes | Composition et procédé associé de mesure de l’observance thérapeutique |
| KR20220008824A (ko) | 2019-04-17 | 2022-01-21 | 컴퍼스 패쓰파인더 리미티드 | 실로시빈으로 불안 장애, 두통 장애 및 섭식 장애를 치료하는 방법 |
| HRP20220797T1 (hr) * | 2019-11-07 | 2022-10-14 | Small Pharma Ltd | Spojevi |
| WO2021168133A1 (en) | 2020-02-19 | 2021-08-26 | Nevakar Inc. | Isoproterenol compositions and methods |
| US11400045B2 (en) | 2020-03-16 | 2022-08-02 | Nasus Pharma Ltd. | Treatment with powdered intranasal epinephrine |
| IL312785B2 (en) | 2020-05-19 | 2026-06-01 | Cybin Irl Ltd | Deuterated tryptamine derivatives and methods of use |
| KR20230071131A (ko) * | 2020-08-17 | 2023-05-23 | 더 트러스티스 오브 컬럼비아 유니버시티 인 더 시티 오브 뉴욕 | 도파민 기능의 바이오마커로서 뉴로멜라닌-민감성 mri의 용도 |
| EP4222501A1 (en) * | 2020-10-24 | 2023-08-09 | Universitätsspital Basel | Method of quantifying lysergic acid diethylamide (lsd) and 2,3-dihydro-3-hydroxy-2-oxo lysergide (o-h-lsd) in human plasma |
| US12029718B2 (en) | 2021-11-09 | 2024-07-09 | Cct Sciences, Llc | Process for production of essentially pure delta-9-tetrahydrocannabinol |
| CN112690771B (zh) * | 2020-12-09 | 2022-05-24 | 华南理工大学 | 一种利用线性回归模型的人脸视频心率检测方法 |
| CN117098496A (zh) | 2021-03-11 | 2023-11-21 | 人类生物科学股份有限公司 | 用于协调包括生物标志物的成像数据集的系统、装置和方法 |
| CN113017632B (zh) * | 2021-03-17 | 2022-11-11 | 陈思 | 一种智慧校园心理咨询辅助方法及系统 |
| WO2023168023A1 (en) | 2022-03-04 | 2023-09-07 | Reset Pharmaceuticals, Inc. | Co-crystals or salts comprising psilocin |
| WO2024056079A1 (zh) | 2022-09-16 | 2024-03-21 | 江苏亚虹医药科技股份有限公司 | 内匹司他酸加成盐的多晶型及其制备方法和用途 |
| WO2024178082A2 (en) * | 2023-02-22 | 2024-08-29 | Freedom Biosciences, Inc. | Composition of opioid receptor modulator and mdma for use thereof |
| CN120754106B (zh) * | 2025-09-02 | 2025-12-09 | 合肥工业大学 | 化合物sch23390在制备治疗铅中毒药物中的应用 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH03500411A (ja) * | 1987-10-07 | 1991-01-31 | マトリックス テクノロジーズ インコーポレーテッド | コカイン中毒の処置および治療薬 |
| JP2000506832A (ja) * | 1996-02-23 | 2000-06-06 | ファーム―エコ ラボラトリーズ，インコーポレイテッド | 選択的なｄ１ドーパミンレセプターアゴニスト及び部分的アゴニスト／アンタゴニスト |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5593367A (en) * | 1995-08-18 | 1997-01-14 | Deere & Company | Switchable ignition and starter control system |
| US5958896A (en) * | 1997-08-08 | 1999-09-28 | The Mclean Hospital | Cytidine-containing and cytosine-containing compounds as treatments for stimulant exposure |
| US6541520B1 (en) * | 1998-08-05 | 2003-04-01 | Brookhaven Science Associates | Treatment of addiction and addiction-related behavior |
| NZ539400A (en) * | 2001-01-17 | 2006-04-28 | Hythiam Inc | Use of flumazenil in developing a drug for the treatment of alcohol dependence |
| AU2002245613A1 (en) * | 2001-03-07 | 2002-09-24 | The Mclean Hospital Corporation | Methods and reagents for identifying compounds and mutations that modulate dopamine beta-hydroxylase activity |
| SE0104388D0 (sv) * | 2001-12-27 | 2001-12-27 | Pharmacia Ab | New formulation and use and manufacture thereof |
| CA2516618A1 (en) * | 2003-02-27 | 2004-09-10 | Shirankai Kyoto University Faculty Of Medicine Alumni Association Inc. | Pharmaceutical composition for treatment of drug dependence |
| RU2252756C1 (ru) * | 2003-12-23 | 2005-05-27 | Хохлов Александр Петрович | Препарат против алкоголизма и наркомании, способ получения такого препарата |
| US20100105748A1 (en) * | 2007-03-16 | 2010-04-29 | David Weinshenker | Methods and compositions for treatment of drug addiction |
| MX2010000938A (es) * | 2007-07-23 | 2010-07-01 | Synosia Therapeutics Inc | Uso de (4-metoxi-7-morfolin-4-il-benzotiazol-2-il)-amida del ácido 4-hidroxi-4-metil-piperidin-1-carboxílico para el tratamiento del trastorno por estrés postraumático. |
| NZ583193A (en) * | 2007-07-23 | 2012-05-25 | Biotie Therapies Inc | Treatment of post-traumatic stress disorder with nepicastat |
| WO2009015244A1 (en) * | 2007-07-23 | 2009-01-29 | Synosia Therapeutics | Rufinamide for the treatment of post-traumatic stress disorder |
| RU2491067C2 (ru) | 2007-08-06 | 2013-08-27 | Байотай Терапис, Инк | Способы лечения зависимости |
| CN101874128B (zh) | 2007-11-26 | 2012-07-04 | 株式会社普利司通 | 铜-锌合金电镀浴及使用其的镀敷方法 |
-
2008
- 2008-08-06 RU RU2010108249/15A patent/RU2491067C2/ru active
- 2008-08-06 EP EP08797300.4A patent/EP2182804B1/en not_active Not-in-force
- 2008-08-06 ES ES08797300.4T patent/ES2638190T3/es active Active
- 2008-08-06 MX MX2010001390A patent/MX2010001390A/es not_active Application Discontinuation
- 2008-08-06 JP JP2010520285A patent/JP2010535801A/ja active Pending
- 2008-08-06 SG SG10201705968RA patent/SG10201705968RA/en unknown
- 2008-08-06 MX MX2015009454A patent/MX357542B/es unknown
- 2008-08-06 CN CN200880109939A patent/CN101815438A/zh active Pending
- 2008-08-06 BR BRPI0815089-3A2A patent/BRPI0815089A2/pt not_active IP Right Cessation
- 2008-08-06 CN CN201611204491.7A patent/CN106983747A/zh active Pending
- 2008-08-06 WO PCT/US2008/072357 patent/WO2009021055A1/en not_active Ceased
- 2008-08-06 US US12/187,166 patent/US20090041800A1/en not_active Abandoned
- 2008-08-06 AU AU2008283903A patent/AU2008283903B2/en not_active Ceased
- 2008-08-06 SG SG2012058210A patent/SG183696A1/en unknown
- 2008-08-06 MX MX2018008628A patent/MX391921B/es unknown
- 2008-08-06 CA CA2695372A patent/CA2695372C/en not_active Expired - Fee Related
- 2008-08-06 NZ NZ583192A patent/NZ583192A/en not_active IP Right Cessation
- 2008-08-06 EP EP17165804.0A patent/EP3251670A1/en not_active Withdrawn
-
2010
- 2010-02-04 MX MX2022001510A patent/MX2022001510A/es unknown
- 2010-02-26 CO CO10023191A patent/CO6260015A2/es not_active Application Discontinuation
-
2013
- 2013-12-06 US US14/099,882 patent/US10561638B2/en not_active Expired - Fee Related
-
2014
- 2014-05-23 JP JP2014107381A patent/JP2014148551A/ja active Pending
-
2015
- 2015-09-22 PH PH12015502210A patent/PH12015502210A1/en unknown
-
2016
- 2016-08-23 JP JP2016162881A patent/JP2016210798A/ja active Pending
-
2018
- 2018-02-08 IL IL257418A patent/IL257418A/en unknown
- 2018-06-06 JP JP2018108758A patent/JP2018154645A/ja active Pending
-
2020
- 2020-01-07 US US16/736,609 patent/US20200383951A1/en not_active Abandoned
- 2020-05-01 JP JP2020081105A patent/JP2020114883A/ja active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH03500411A (ja) * | 1987-10-07 | 1991-01-31 | マトリックス テクノロジーズ インコーポレーテッド | コカイン中毒の処置および治療薬 |
| JP2000506832A (ja) * | 1996-02-23 | 2000-06-06 | ファーム―エコ ラボラトリーズ，インコーポレイテッド | 選択的なｄ１ドーパミンレセプターアゴニスト及び部分的アゴニスト／アンタゴニスト |
Non-Patent Citations (3)
| Title |
|---|
| JPN6013019509; Ｊ． Ｍｅｄ． Ｃｈｅｍ． Ｖｏｌ．４９, 2006, ｐｐ．１１９１-１１９７ * |
| JPN6013019511; Ｂｒ． Ｊ． Ｐｈａｒｍａｃｏｌ． Ｖｏｌ．１２１, 1997, ｐｐ．１８０３-１８０９ * |
| JPN6013019512; Ｃｌｉｎ． Ｎｅｕｒｏｓｃｉ． Ｒｅｓ． Ｖｏｌ．５, 2005, ｐｐ．１６９-１７３ * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3251670A1 (en) | 2017-12-06 |
| MX2010001390A (es) | 2010-08-02 |
| JP2020114883A (ja) | 2020-07-30 |
| US20140099336A1 (en) | 2014-04-10 |
| EP2182804B1 (en) | 2017-05-24 |
| SG10201705968RA (en) | 2017-08-30 |
| ES2638190T3 (es) | 2017-10-19 |
| CN106983747A (zh) | 2017-07-28 |
| PH12015502210A1 (en) | 2017-04-10 |
| JP2014148551A (ja) | 2014-08-21 |
| NZ583192A (en) | 2012-06-29 |
| MX357542B (es) | 2018-07-13 |
| WO2009021055A1 (en) | 2009-02-12 |
| IL257418A (en) | 2018-04-30 |
| US20200383951A1 (en) | 2020-12-10 |
| CO6260015A2 (es) | 2011-03-22 |
| CN101815438A (zh) | 2010-08-25 |
| BRPI0815089A2 (pt) | 2014-09-30 |
| CA2695372A1 (en) | 2009-02-12 |
| MX391921B (es) | 2025-03-21 |
| JP2018154645A (ja) | 2018-10-04 |
| JP2016210798A (ja) | 2016-12-15 |
| SG183696A1 (en) | 2012-09-27 |
| MX2022001510A (es) | 2022-08-11 |
| RU2491067C2 (ru) | 2013-08-27 |
| AU2008283903A1 (en) | 2009-02-12 |
| US20090041800A1 (en) | 2009-02-12 |
| CA2695372C (en) | 2013-01-22 |
| EP2182804A4 (en) | 2010-12-22 |
| AU2008283903B2 (en) | 2014-01-16 |
| RU2010108249A (ru) | 2011-09-20 |
| US10561638B2 (en) | 2020-02-18 |
| EP2182804A1 (en) | 2010-05-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018154645A (ja) | 依存症治療方法 | |
| RU2458691C2 (ru) | Лечение посттравматического стрессового расстройства | |
| EP4346788A2 (en) | Enantiomeric entactogen compositions and methods of their use | |
| Lefebvre et al. | The influence of CYP2D6 phenotype on the clinical response of nebivolol in patients with essential hypertension | |
| WO2010124089A2 (en) | Methods for treating dependence | |
| HUT77315A (hu) | Loratadinszármazék allergiás és egyéb betegségek kezelésében való alkalmazásra | |
| Blough et al. | Alpha-ethyltryptamines as dual dopamine–serotonin releasers | |
| MX2013005705A (es) | Tratamiento terapeutico para sindrome metabolico, diabetes tipo 2, obesidad, o prediabetes. | |
| Chiou et al. | 9-hydroxycanthin-6-one induces penile erection and delays ejaculation | |
| AU2018203524B2 (en) | Methods for treating dependence | |
| US20050277626A1 (en) | Methods and compositions for treatment of nicotine dependence and dementias | |
| WO2022232104A1 (en) | Methods of treatment with neuroactive steroids | |
| AU2014202047A1 (en) | Methods for treating dependence | |
| AU2014207347A1 (en) | Isometheptene isomer | |
| HK1241721A1 (en) | Methods for treating dependence | |
| HK1143038A (en) | Methods for treating dependence | |
| HK1155063A (en) | Treatment of post-traumatic stress disorder | |
| Alanazi et al. | Methamphetamine Use: Neurochemical Effects Health Outcomes and Addiction Trajectories |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110617 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20110617 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20121107 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130507 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130805 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130812 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130906 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20140204 |